AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26312852 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 28
Study 26312852 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir (8 g daily)
Number of subjects: 28
Study 26312908 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 34198
Study 26312919 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed loop insulin delivery
Number of subjects: 40
Study 26313170 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiolabeled human serum albumin
Number of subjects: 10
Study 26313245 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic mycophenolate mofetil (MMF)
Number of subjects: 235
Study 26313245 — intervention group
Group type: COMPARATOR
Intervention: Topical cyclosporine A (CsA)
Number of subjects: 235
Study 26313245 — intervention group
Group type: COMPARATOR
Intervention: Topical tacrolimus
Number of subjects: 235
Study 26313402 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfocused ultrasound (MFU)
Number of subjects: 52
Study 26313445 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) 60 mg once daily plus PEG-IFN 180 µg weekly and RBV 1,000-1,200 mg/day (weight-based) twice daily
Number of subjects: 124
Study 26313445 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFN/RBV (placebo group)
Number of subjects: 124
Study 26313445 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) plus PEG-IFN/RBV
Number of subjects: 124
Study 26313683 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-CRT pathologic stage 0
Number of subjects: 140
Study 26313683 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-CRT pathologic stage I
Number of subjects: 140
Study 26313683 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-CRT pathologic stage II
Number of subjects: 140
Study 26313683 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-CRT pathologic stage III
Number of subjects: 140
Study 26313683 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-CRT pathologic stage ypT0N1-2
Number of subjects: 140
Study 26314396 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 72
Study 26314396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 26314624 — intervention group
Group type: EXPERIMENTAL
Intervention: 17D-204 yellow fever vaccine (Stamaril, Sanofi-Pasteur, Lyon, France), 8 vials of lyophilized vaccine, viral quantification, cloning and sequencing of C/prM/E region.
Number of subjects: 0
Study 26314729 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose challenge
Number of subjects: 214
Study 26314729 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lipid challenge
Number of subjects: 214
Study 26314729 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between lipid and glucose challenges
Number of subjects: 214
Study 26314729 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 214
Study 26314740 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized measurement of CRP levels with enhanced CT-scan if CRP exceeds 140 mg/L on postoperative day 3, 4, or 5.
Number of subjects: 0
Study 26314740 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative monitoring (control group).
Number of subjects: 0
Study 26314740 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized measurement of CRP levels.
Number of subjects: 0
Study 26314822 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant injection
Number of subjects: 170
Study 26314822 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant injection (2 or 3 injections)
Number of subjects: 170
Study 26315282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic leg extensor muscle power
Number of subjects: 190
Study 26315282 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle strength
Number of subjects: 190
Study 26315448 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical macular edema
Number of subjects: 194
Study 26315448 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical macular edema
Number of subjects: 194
Study 26315448 — intervention group
Group type: COMPARATOR
Intervention: Diabetic eyes without macular edema
Number of subjects: 194
Study 26315448 — intervention group
Group type: COMPARATOR
Intervention: Diabetic patients with normal OCT
Number of subjects: 194
Study 26315448 — intervention group
Group type: COMPARATOR
Intervention: Healthy eyes
Number of subjects: 194
Study 26315560 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical macular edema in type 2 diabetic eyes with mild NPDR
Number of subjects: 48
Study 26315560 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression to clinical macular edema
Number of subjects: 48
Study 26315560 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular disease activity (MA turnover ≥6)
Number of subjects: 48
Study 26315712 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) primary prophylaxis (PP) planned in patients with FN risk at or above 20% threshold.
Number of subjects: 944
Study 26315712 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors considered by physicians when assessing FN risk.
Number of subjects: 944
Study 26315712 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized FN risk assessment.
Number of subjects: 944
Study 26315732 — intervention group
Group type: EXPERIMENTAL
Intervention: Final Kissing Ballooning (FKB)
Number of subjects: 1901
Study 26315732 — intervention group
Group type: COMPARATOR
Intervention: Non-Final Kissing Ballooning (non-FKB)
Number of subjects: 1901
Study 26315740 — intervention group
Group type: EXPERIMENTAL
Intervention: CoreValve Evolut R TAVR system (26- or 29-mm valve)
Number of subjects: 60
Study 26315743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis using 24 mg of tissue-plasminogen activator (t-PA) administered as 1 mg/h for 24 h with a unilateral catheter or 1 mg/h/catheter for 12 h with bilateral catheters.
Number of subjects: 150
Study 26315931 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapies (fludarabine/cyclophosphamide/rituximab)
Number of subjects: 1558
Study 26315931 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapies (bendamustine/rituximab)
Number of subjects: 1558
Study 26315931 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapies without an antibody (fludarabine/cyclophosphamide)
Number of subjects: 1558
Study 26315931 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapies without an antibody (fludarabine)
Number of subjects: 1558
Study 26315931 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapies without an antibody (chlorambucil)
Number of subjects: 1558
Study 26315931 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one antibody-containing regimen
Number of subjects: 1558
Study 26315931 — intervention group
Group type: COMPARATOR
Intervention: No antibody treatment
Number of subjects: 1558
Study 26315931 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive chemo(immuno)therapy combinations (e.g. cyclophosphamide/doxorubicin/vincristine/prednisone)
Number of subjects: 1558
Study 26315931 — intervention group
Group type: COMPARATOR
Intervention: Single agent chemotherapy (e.g. fludarabine)
Number of subjects: 1558
Study 26315931 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemoimmunotherapy (e.g. fludarabine/cyclophosphamide/rituximab)
Number of subjects: 1558
Study 26315949 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry and reversibility tests
Number of subjects: 3133
Study 26315949 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up investigation of newly defined obstructive pulmonary disease patients
Number of subjects: 3133
Study 26315949 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive RESPECT database
Number of subjects: 3133
Study 26315953 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline dynamic parameters (flexion/extension cone relative to a fixed C-7, center of rotation [COR], and range of motion arc relative to the COR)
Number of subjects: 110
Study 26315953 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal parameters including increased C-7 sagittal translation over T-1 (slip)
Number of subjects: 110
Study 26315953 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagittal slip at C-2 and C-4
Number of subjects: 110
Study 26315953 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced flexion/extension motion cones, more posterior COR, and smaller range of motion
Number of subjects: 110
Study 26315967 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing TKI therapy after RECIST progression
Number of subjects: 123
Study 26315967 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of TKI therapy after RECIST progression
Number of subjects: 123
Study 26316262 — intervention group
Group type: EXPERIMENTAL
Intervention: Central medial femorotibial compartment cartilage thickness loss
Number of subjects: 600
Study 26316262 — intervention group
Group type: EXPERIMENTAL
Intervention: Central femur cartilage thickness loss
Number of subjects: 600
Study 26316262 — intervention group
Group type: EXPERIMENTAL
Intervention: Central tibia cartilage thickness loss
Number of subjects: 600
Study 26316262 — intervention group
Group type: COMPARATOR
Intervention: Lateral femorotibial compartment cartilage thickness loss
Number of subjects: 600
Study 26316385 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg/day liposomal amphotericin B (L-AMB) monotherapy for 1 month
Number of subjects: 40
Study 26316523 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial Infarction (MI)
Number of subjects: 80
Study 26316523 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment elevation MI
Number of subjects: 80
Study 26316523 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak plasma troponin concentrations
Number of subjects: 80
Study 26316557 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 0
Study 26316557 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 26317543 — intervention group
Group type: EXPERIMENTAL
Intervention: MTKI treatment
Number of subjects: 58
Study 26317543 — intervention group
Group type: EXPERIMENTAL
Intervention: SUMSCAN favorable patients
Number of subjects: 58
Study 26317981 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 7
Study 26317981 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 7
Study 26318254 — intervention group
Group type: EXPERIMENTAL
Intervention: Verproside
Number of subjects: 0
Study 26318254 — intervention group
Group type: EXPERIMENTAL
Intervention: Verproside combined with IKK inhibitor (BAY11-7082)
Number of subjects: 0
Study 26318254 — intervention group
Group type: EXPERIMENTAL
Intervention: Verproside combined with TAK1 inhibitor (5z-7-oxozeaenol)
Number of subjects: 0
Study 26318833 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided FNA biopsy of the muscularis propria
Number of subjects: 11
Study 26318833 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided FNA biopsy
Number of subjects: 11
Study 26318833 — intervention group
Group type: COMPARATOR
Intervention: Surgical full-thickness biopsy
Number of subjects: 11
Study 26321198 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless cardiac pacemaker implantation
Number of subjects: 526
Study 26321472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) administration of FdCyd and THU
Number of subjects: 0
Study 26321472 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral (PO) administration of FdCyd after THU
Number of subjects: 0
Study 26321472 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot study in humans
Number of subjects: 0
Study 26321472 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of THU with FdCyd
Number of subjects: 0
Study 26321501 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT studies (baseline, interim, post-CTRT)
Number of subjects: 31
Study 26321501 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline TLG
Number of subjects: 31
Study 26321501 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔTLG post-CTRT
Number of subjects: 31
Study 26321596 — intervention group
Group type: EXPERIMENTAL
Intervention: Aorfix endograft (EVAR)
Number of subjects: 0
Study 26322311 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmer conditions (26-27°C)
Number of subjects: 20
Study 26322311 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (19-20°C)
Number of subjects: 20
Study 26322311 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (gender comparison)
Number of subjects: 20
Study 26322311 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral temperature (mediating effect)
Number of subjects: 20
Study 26322512 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-resistance monitoring
Number of subjects: 10
Study 26322512 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined prediction model (change in resistance >8.8% or non-laminar result)
Number of subjects: 10
Study 26323022 — intervention group
Group type: EXPERIMENTAL
Intervention: Additive-enhanced diet (phosphorus additives)
Number of subjects: 10
Study 26323022 — intervention group
Group type: COMPARATOR
Intervention: Low-additive diet (no phosphorus additives)
Number of subjects: 10
Study 26323022 — intervention group
Group type: EXPERIMENTAL
Intervention: High-phosphorus diet in mice
Number of subjects: 10
Study 26323282 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h copeptin
Number of subjects: 1439
Study 26323282 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h hs-cTnT
Number of subjects: 1439
Study 26324051 — intervention group
Group type: EXPERIMENTAL
Intervention: Short messaging service (SMS) text messages used as workshop reminders, post-workshop message reinforcement, spiritual/motivational messages, and participant retention.
Number of subjects: 0
Study 26324363 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 10 mg administered on a 7-days-on/7-days-off schedule
Number of subjects: 65
Study 26324363 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 (various doses from 0.5 to 12 mg)
Number of subjects: 65
Study 26324363 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 (various doses)
Number of subjects: 65
Study 26324363 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 12 mg daily
Number of subjects: 65
Study 26324363 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 9 mg daily
Number of subjects: 65
Study 26324363 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 10 mg on a 7-days-on/7-days-off schedule
Number of subjects: 65
Study 26324363 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 (starting at 4 mg daily)
Number of subjects: 65
Study 26325106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimonidazole (administered intravenously 16-20 hours before surgery)
Number of subjects: 10
Study 26327127 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined coronary CT angiography (CTA) and myocardial CT perfusion (CTP)
Number of subjects: 90
Study 26327481 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose to the thyroid (up to 0.2 Gy)
Number of subjects: 4338
Study 26327481 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical or radiological splenectomy (>20 Gy to the spleen)
Number of subjects: 4338
Study 26327481 — intervention group
Group type: EXPERIMENTAL
Intervention: High radiation doses (>5 Gy) to pituitary gland
Number of subjects: 4338
Study 26327481 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrosourea chemotherapy
Number of subjects: 4338
Study 26327481 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose to the thyroid
Number of subjects: 4338
Study 26327481 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) at time of interview >= 25 kg/m(2)
Number of subjects: 4338
Study 26327481 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) at time of interview < 25 kg/m(2)
Number of subjects: 4338
Study 26327694 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib (20S proteasome inhibitor)
Number of subjects: 0
Study 26327694 — intervention group
Group type: EXPERIMENTAL
Intervention: 19S proteasome regulator knockdown
Number of subjects: 0
Study 26327916 — intervention group
Group type: EXPERIMENTAL
Intervention: HCEE academic sites
Number of subjects: 197
Study 26327916 — intervention group
Group type: COMPARATOR
Intervention: CI sites
Number of subjects: 197
Study 26327916 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 197
Study 26327916 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HCEE and CI sites
Number of subjects: 197
Study 26329464 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured counselling session by gynaecologists
Number of subjects: 1871
Study 26330288 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive armodafinil 150 mg/day
Number of subjects: 399
Study 26330288 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 399
Study 26330414 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 1937360
Study 26330425 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 6784
Study 26330458 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ788 (3 mg, single intralesional application)
Number of subjects: 5
Study 26330458 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ788 (cumulative dosage of 8 mg)
Number of subjects: 5
Study 26330458 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ788 (cumulative dosage of 10 mg)
Number of subjects: 5
Study 26330458 — intervention group
Group type: COMPARATOR
Intervention: PBS (control lesions)
Number of subjects: 5
Study 26331103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training for 6 months (in TC-naïve adults)
Number of subjects: 87
Study 26331103 — intervention group
Group type: COMPARATOR
Intervention: Long-term Tai Chi practice (in TC experts)
Number of subjects: 87
Study 26331432 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 75 mg/m² on days 1 and 2, lenalidomide 25 mg on days 1-21, dexamethasone 40 mg on days 1, 8, 15, and 22
Number of subjects: 71
Study 26331432 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine, lenalidomide, and dexamethasone
Number of subjects: 71
Study 26331768 — intervention group
Group type: EXPERIMENTAL
Intervention: elosulfase alfa 2.0 mg/kg/week for 52 weeks
Number of subjects: 15
Study 26332545 — intervention group
Group type: EXPERIMENTAL
Intervention: Imetelstat (9.4 mg/kg body weight, intravenous infusion every 1 to 3 weeks)
Number of subjects: 33
Study 26332545 — intervention group
Group type: EXPERIMENTAL
Intervention: Imetelstat
Number of subjects: 33
Study 26332546 — intervention group
Group type: EXPERIMENTAL
Intervention: Imetelstat (7.5 or 9.4 mg/kg intravenously once a week)
Number of subjects: 18
Study 26332546 — intervention group
Group type: EXPERIMENTAL
Intervention: Imetelstat
Number of subjects: 18
Study 26332547 — intervention group
Group type: EXPERIMENTAL
Intervention: Takotsubo cardiomyopathy
Number of subjects: 1750
Study 26332874 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 100
Study 26333343 — intervention group
Group type: EXPERIMENTAL
Intervention: sNGAL ≥179 ng/mL at 6 hours
Number of subjects: 458
Study 26333343 — intervention group
Group type: COMPARATOR
Intervention: sNGAL <179 ng/mL and sCr <0.3 mg/dL
Number of subjects: 458
Study 26333343 — intervention group
Group type: EXPERIMENTAL
Intervention: sNGAL ≥179 ng/mL
Number of subjects: 458
Study 26333343 — intervention group
Group type: EXPERIMENTAL
Intervention: sCr ≥0.3 mg/dL
Number of subjects: 458
Study 26333343 — intervention group
Group type: COMPARATOR
Intervention: sNGAL <179 ng/mL and sCr increase <0.3 mg/dL
Number of subjects: 458
Study 26333343 — intervention group
Group type: EXPERIMENTAL
Intervention: sNGAL ≥179 ng/mL and sCr increase <0.3 mg/dL
Number of subjects: 458
Study 26333343 — intervention group
Group type: EXPERIMENTAL
Intervention: sCr increase ≥0.3 mg/dL
Number of subjects: 458
Study 26333343 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine NGAL <20 ng/mL and sNGAL <179 ng/mL at 6 hours
Number of subjects: 458
Study 26333941 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term Antiretroviral Therapy (ART)
Number of subjects: 334
Study 26334219 — intervention group
Group type: EXPERIMENTAL
Intervention: VS-6063 (425 mg b.i.d.)
Number of subjects: 46
Study 26334219 — intervention group
Group type: EXPERIMENTAL
Intervention: VS-6063 (300-425 mg b.i.d.)
Number of subjects: 46
Study 26334219 — intervention group
Group type: EXPERIMENTAL
Intervention: VS-6063 (various doses)
Number of subjects: 46
Study 26334219 — intervention group
Group type: EXPERIMENTAL
Intervention: VS-6063 (500-750 mg b.i.d.)
Number of subjects: 46
Study 26334382 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA-CTP
Number of subjects: 381
Study 26334382 — intervention group
Group type: COMPARATOR
Intervention: CTA
Number of subjects: 381
Study 26334382 — intervention group
Group type: COMPARATOR
Intervention: CTP
Number of subjects: 381
Study 26334761 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived social standing
Number of subjects: 495
Study 26334761 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 495
Study 26334761 — intervention group
Group type: EXPERIMENTAL
Intervention: African American race
Number of subjects: 495
Study 26334761 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 495
Study 26334761 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower medication adherence
Number of subjects: 495
Study 26334878 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with 8.5 g/day of RS type 2 for 4 weeks
Number of subjects: 18
Study 26335027 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 19
Study 26335027 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatmax training
Number of subjects: 19
Study 26335066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundus photography
Number of subjects: 165
Study 26335066 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral-domain optical coherence tomography (SD-OCT)
Number of subjects: 165
Study 26335066 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural parameters related to severity of papilledema
Number of subjects: 165